A recent study suggests that people who come off new weight-loss injections like semaglutide or tirzepatide may regain shed pounds far faster than those who stop traditional lifestyle plans.
Research printed in a major medical journal demonstrates that while obese people often shed about a fifth of their body weight while using the jabs, the mass comes back at an estimated rate of nearly a kilo each month once they quit.
"Individuals using these medications must be cognizant of the risk of quick rebound weight gain when the therapy is stopped," stated lead investigator Dr. Susan Jebb.
That rate of regain implies a reversion to pre-treatment mass in about a year and a half.
Analyzing Approaches
The research, which reviewed dozens of trials involving over 9,000 of patients, compared the effects of GLP-1 agonists with other pills.
The team emphasize that people who lose weight through dieting generally experience a more gradual weight regain—approximately 100 grams monthly—after stopping.
Understanding the Quick Regain
Nutrition scientists believe the mode of action of the jabs accounts for the accelerated regain.
GLP-1 drugs mimic a natural hormone called GLP-1, which moderates appetite.
"Artificially providing GLP-1 concentrations far above than the body's typical production might result in the system to produce less of its own natural hormone, and could reduce sensitivity to its effects," said Dr. Adam Collins, a nutrition expert.
"Stopping of this medication leads to appetite is unsuppressed, making excessive eating far more likely."
An Ongoing Disease?
Medical guidelines advise the jabs for individuals with obesity-related health risks, accompanied by prescribed lifestyle changes.
Professionals argue that, due to the high risk of relapse, the treatment should be considered long-term.
This view is supported by pharmaceutical companies, who note that the results "emphasize the long-term character of excess weight," comparing it to managing conditions like diabetes.
Patient Accounts
Individuals who have discontinued the medication report a sudden resurgence of cravings.
"It was like a switch that goes on and you're instantly extremely hungry," described a patient.
The struggle is exacerbated if users have not adopted sustainable dietary or behavioural modifications during treatment.
Widespread Adoption
Survey data suggest that a significant number of people in the UK have used weight-loss jabs in the last 12 months, with interest remaining high.
- Adoption is higher among females than men.
- The middle-aged demographic shows the greatest usage rates.
- Many obtain the medications through private healthcare rather than public health services.
In conclusion, researchers stress that while these medications are potent agents for weight loss, they are not a magic cure and lasting health benefits likely depends on integrated behavioural support.
